Saxenda vs Retatrutide: Side-Effect Profile Head-to-Head

How These Two Drugs Work Differently

Saxenda and retatrutide belong to different generations of incretin-based therapies, and their side-effect profiles reflect fundamentally different pharmacology. Understanding the receptor-level differences explains why the tolerability data diverge.

Saxenda: Single-Receptor GLP-1 Agonist

Saxenda is a once-daily injectable delivering liraglutide at 3 mg, the same molecule used in Victoza (1.2 or 1.8 mg) for type 2 diabetes but at a higher dose 1. It activates the GLP-1 receptor exclusively, slowing gastric emptying, reducing appetite via hypothalamic signaling, and stimulating insulin secretion in a glucose-dependent manner 2. The FDA approved Saxenda in December 2014 for adults with BMI ≥30 or BMI ≥27 with at least one weight-related comorbidity 3.

Retatrutide: Triple-Hormone Receptor Agonist

Retatrutide activates three receptors simultaneously: GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon 4. The glucagon receptor component is what separates retatrutide from dual agonists like tirzepatide. Glucagon receptor activation increases hepatic energy expenditure and lipolysis, which may explain the substantially greater weight loss observed in trials 5. That same triple activation also creates additional pathways for side effects not seen with GLP-1-only drugs.

Gastrointestinal Side Effects: The Primary Concern

GI events dominate the adverse-event profiles of both drugs. They are the most frequent reason patients consider discontinuing treatment, and the most common topic in clinical consultations about these medications.

Nausea Rates Across Dose Levels

In the SCALE Obesity and Prediabetes trial (N=3,731), 39.3% of participants on Saxenda 3 mg reported nausea compared to 13.8% on placebo 1. Most nausea occurred during the first 4 to 8 weeks of dose escalation and was mild to moderate in severity 6.

In the Jastreboff et al. Phase 2 trial of retatrutide (N=338), nausea rates were dose-dependent: 16.7% at 1 mg, 38.9% at 4 mg (maintenance dose), and 45.2% at the highest tested dose of 12 mg 4. At the 8 mg dose level, nausea affected 34.3% of participants.

Vomiting and Diarrhea

Vomiting occurred in 15.7% of Saxenda-treated patients versus 3.5% on placebo in the SCALE trial 1. For retatrutide at 12 mg, vomiting reached 19.4%, while diarrhea was reported in 25.8% 4. Diarrhea rates on Saxenda were lower, at approximately 11% in the key program 3. The glucagon receptor component of retatrutide may contribute to the higher diarrhea signal through altered bile acid metabolism and intestinal motility 7.

Constipation

An often-overlooked GI effect. Saxenda caused constipation in approximately 11% of treated patients 3. Retatrutide's phase 2 data showed constipation in 6.5% to 12.9% of participants depending on dose 4. The simultaneous GIP receptor activation in retatrutide may partially offset constipation, as GIP signaling can accelerate intestinal transit 8.

Discontinuation Rates and Tolerability

Discontinuation data offer the clearest measure of real-world tolerability because they capture the point at which side effects become intolerable for patients.

Trial Dropout Numbers

In the SCALE trial, 9.9% of Saxenda-treated participants discontinued due to adverse events, compared to 3.8% on placebo 1. GI events accounted for the majority of those dropouts.

Retatrutide's phase 2 trial reported a 6% overall discontinuation rate due to adverse events across all dose groups 4. This number appears lower than Saxenda's, but the comparison is imperfect. Phase 2 trials typically enroll more motivated participants, have smaller sample sizes, and use more intensive monitoring than phase 3 key studies. The TRIUMPH phase 3 program for retatrutide will provide more definitive tolerability data 9.

Dose Titration and GI Mitigation

Both drugs use a stepwise dose-escalation schedule to reduce GI side effects. Saxenda escalates from 0.6 mg weekly until reaching 3 mg over 4 weeks 3. Retatrutide used a similar strategy in its phase 2 trial, with titration periods of up to 24 weeks for the 12 mg dose 4. The longer titration in the retatrutide arm may partially account for its lower discontinuation rate despite higher peak GI event rates.

Hepatobiliary and Pancreatic Safety

Both GLP-1 agonists carry theoretical and observed risks to the pancreas and gallbladder. These are the side effects that generate the most clinical concern, even though they occur at low absolute rates.

Pancreatitis

The Saxenda prescribing label includes a warning for acute pancreatitis 3. In pooled clinical trial data, pancreatitis occurred in 0.3% of liraglutide-treated patients versus 0.1% on placebo. A large cardiovascular outcomes trial of liraglutide 1.8 mg (LEADER, N=9,340) found no statistically significant increase in pancreatitis over 3.8 years of follow-up 10. No cases of pancreatitis were reported in the retatrutide phase 2 trial 4, though the sample size (N=338) was too small to detect rare events.

Gallbladder Events

Cholelithiasis (gallstones) is a class effect of rapid weight loss and GLP-1 agonism. Saxenda's key program identified gallbladder-related events in 2.5% of treated patients versus 1.0% on placebo 3. Retatrutide's phase 2 data did not report a specific gallbladder event rate, but the magnitude of weight loss (up to 24.2% at 12 mg) means the risk is likely at least comparable 4. Clinicians monitoring patients on retatrutide should watch for right upper quadrant pain, particularly after the first 12 weeks of treatment when weight loss velocity is highest.

Hepatic Effects Unique to Retatrutide

The glucagon receptor component of retatrutide has a direct hepatic effect. In the phase 2 trial, retatrutide reduced liver fat content by up to 81.4% from baseline (measured by MRI-PDFF), suggesting a potential therapeutic role in metabolic dysfunction-associated steatotic liver disease 4. Transient elevations in aminotransferases were observed but resolved without intervention 11. Saxenda does not have a glucagon receptor component and shows modest liver fat reduction at best 12.

Cardiovascular and Heart Rate Effects

Heart rate changes are a known pharmacologic effect of GLP-1 receptor agonists. Both drugs cause small but measurable increases.

Resting Heart Rate

Saxenda increased mean resting heart rate by 2.0 to 3.2 beats per minute (bpm) in clinical trials 3. The LEADER trial demonstrated cardiovascular safety for liraglutide 1.8 mg, with a 13% reduction in major adverse cardiovascular events (HR 0.87, 95% CI 0.78 to 0.97) 10. No dedicated cardiovascular outcomes trial has been completed for liraglutide 3 mg specifically, though the FDA considered the LEADER data supportive.

Retatrutide Cardiovascular Data

Retatrutide's phase 2 trial reported heart rate increases of 2 to 4 bpm at the 8 and 12 mg doses 4. No cardiovascular outcomes data exist for retatrutide yet. The TRIUMPH cardiovascular substudy will be the first to address this 9. The glucagon receptor activation could theoretically increase cardiac output, but the GIP component may counterbalance this through vasodilatory effects 13.

Injection-Site Reactions and Practical Tolerability

Beyond systemic effects, the daily injection burden of Saxenda versus the once-weekly dosing of retatrutide creates a meaningful difference in patient experience.

Injection Frequency and Site Reactions

Saxenda requires daily subcutaneous injections, while retatrutide is dosed once weekly 3 4. In the SCALE program, injection-site reactions (erythema, pain, pruritus) occurred in approximately 13.9% of Saxenda patients 3. Retatrutide's phase 2 trial reported injection-site reactions in approximately 5% of participants 4. The lower rate likely reflects fewer total injections per treatment period (48 vs 365 over one year) rather than a fundamental difference in local tolerability.

Anti-Drug Antibodies

Liraglutide generates anti-drug antibodies in approximately 8.6% of patients, though these are rarely neutralizing and have not been associated with reduced efficacy or safety signals 3. Immunogenicity data for retatrutide from the phase 2 trial have not been fully published 4. The once-weekly dosing pattern of retatrutide may reduce antibody formation compared to daily administration, consistent with observations in other weekly GLP-1 agonists like semaglutide 14.

Metabolic Side Effects: Blood Glucose and Thyroid

GLP-1 receptor agonists affect glucose homeostasis and carry a class-wide thyroid warning. These effects differ between the two drugs.

Hypoglycemia Risk

In patients without type 2 diabetes, hypoglycemia rates are low for both drugs. Saxenda's SCALE trial reported hypoglycemia in 1.3% of non-diabetic participants versus 1.0% on placebo 1. Retatrutide showed no clinically significant hypoglycemia events in non-diabetic participants at any dose level 4. In the separate phase 2 diabetes study of retatrutide, hypoglycemia rates rose modestly when combined with metformin 15.

Thyroid C-Cell Concerns

All GLP-1 receptor agonists carry a boxed warning about thyroid C-cell tumors based on rodent data 3. Liraglutide caused dose-dependent thyroid C-cell tumors in rats and mice at clinically relevant exposures. A 2022 analysis of the FDA Adverse Event Reporting System found no increased medullary thyroid carcinoma signal with GLP-1 agonists in humans over a decade of post-marketing surveillance 16. Retatrutide will carry the same class warning upon approval, as the GLP-1 receptor component activates the same pathway. Both drugs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.

Side-Effect Comparison at a Glance

| Side Effect | Saxenda 3 mg | Retatrutide 12 mg | |---|---|---| | Nausea | 39.3% | 45.2% | | Vomiting | 15.7% | 19.4% | | Diarrhea | ~11% | 25.8% | | Constipation | ~11% | 6.5 to 12.9% | | Injection-site reactions | 13.9% | ~5% | | Heart rate increase | 2 to 3.2 bpm | 2 to 4 bpm | | Discontinuation (AE) | 9.9% | ~6% | | Dosing frequency | Daily | Once weekly | | Approval status | FDA-approved (2014) | Investigational |

Sources: SCALE [1], Jastreboff phase 2 [4], Saxenda label [3].

Which Drug Has the Better Safety Profile Overall

Saxenda has 10+ years of post-marketing safety data supporting its use, including a cardiovascular outcomes signal from the LEADER trial 10. Its side-effect profile is well-characterized and predictable.

The Case for Saxenda

Saxenda's advantage is certainty. Clinicians know precisely what to expect, how to manage GI side effects during titration, and which patients to avoid treating (history of pancreatitis, MTC, pregnancy). The drug's lower nausea ceiling (39.3% vs 45.2%) and simpler single-receptor mechanism mean fewer unknown variables 1.

The Case for Retatrutide

Retatrutide's tolerability may ultimately prove comparable or superior on a per-unit-of-weight-loss basis. At 24.2% mean weight loss 4, retatrutide delivers roughly three times the efficacy of Saxenda's 8.0% 1. The ratio of GI side effects to weight loss favors retatrutide. Its once-weekly dosing also eliminates 313 injections per year, reducing cumulative injection-site burden. The missing piece is long-term safety data, which the TRIUMPH phase 3 program is designed to provide 9.

Patients considering these options should discuss both the efficacy-to-tolerability ratio and the maturity of the safety evidence with their prescribing clinician. For patients currently on Saxenda who want greater weight loss, the transition to retatrutide (once approved) would require a washout period guided by liraglutide's half-life of approximately 13 hours 3.